Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion’s Partner OBI Pharma Announces OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

OBI Pharma Annouces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted ADC For Cancer Therapy

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference

Biosion Today Presented BSI-082 Key Data at PEGS Boston Summit